Android app on Google Play

Canaccord Genuity on Biotechnology: Q1 Earnings Preview - What To Expect

April 20, 2012 10:05 AM EDT Send to a Friend
Get Alerts ALXN Hot Sheet
Price: $168.22 +1.05%

Rating Summary:
    11 Buy, 7 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 13 | New: 4
Trade ALXN Now!
Join SI Premium – FREE
Canaccord Genuity on Biotechnology: Q1 Earnings Preview - What To Expect

Analyst, Salveen Richter, said, "Q1/12 EPS is a key event for some, but overshadowed by M&A and binary catalysts for others: We expect Q1/12 earnings to serve as catalysts for Alexion (Nasdaq: ALXN), Dendreon (Nasdaq: DNDN) and potentially Incyte (Nasdaq: INCY) (in-line/beat is anticipated). However, Amylin (Nasdaq: AMLN) and Human Genome (Nasdaq: HGSI) will be buoyed by M&A speculation (rather than EPS), while for Auxilium (Nasdaq: AUXL) and BioMarin (Nasdaq: BMRN) (expect solid top-line Q1) it is all about data. For Savient (Nasdaq: SVNT) and United Therapeutics (Nasdaq: UTHR), company fundamentals will play an important role on top of EPS outlook."

Canaccord rated ALXN, AUXL, BMRN, INCY and UTHR at a 'Buy' rating. DNDN, HGSI, and SVNT at Hold. AMLN at a Sell.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Earnings

Add Your Comment